Association Between Serum FGF23 Levels and Coronary Artery Calcification in Peritoneal Dialysis Patients
International Journal of Clinical Practice · 2026-01 · 2026 (1)
DOI: 10.1155/ijcp/5868344 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Practice, online erschienen am 20.07.2026. Verfasst von Haiying Xie und 11 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Program of Zhejiang Province.
Abstract (Originalsprache)
Background
Cardiovascular disease remains the leading cause of mortality in patients with chronic kidney disease, particularly those receiving dialysis. Fibroblast growth factor 23 (FGF23) has been implicated in vascular calcification and adverse cardiovascular outcomes in hemodialysis populations; however, its role in peritoneal dialysis (PD) patients remains insufficiently characterized. This study aimed to investigate the association between serum FGF23 levels and coronary artery calcification (CAC) in PD patients.
Methods
In this cross‐sectional study, 198 stable PD patients were enrolled between January 2021 and December 2023. Coronary artery calcium scores (CACSs) were assessed using multislice spiral computed tomography, and patients were categorized into three groups (CACS = 0, 1–400, > 400). Serum intact FGF23 levels were measured using a commercial enzyme‐linked immunosorbent assay (ELISA) kit (catalog # DMP200, R&D Systems, USA). Multivariate logistic regression (using a CACS > 400 cutoff to define severe calcification) was performed to evaluate independent associations. Nonlinearity was assessed using restricted cubic spline (RCS) analysis. Predictive performance was evaluated using receiver operating characteristic (ROC) curves.
Results
FGF23 levels increased progressively with CACS severity ( p < 0.001). In multivariate analysis, serum FGF23 remained independently associated with severe coronary calcification (OR per 100 pg/mL increment = 1.10, 95% CI: 1.00–1.22, p = 0.03). RCS analysis demonstrated a nonlinear association with two inflection points (246.16 and 1125.79 pg/mL). Subgroup analyses revealed stronger associations in younger (≤ 65 years) and female patients. Population attributable fraction analysis suggested substantial attributable risk in selected subgroups. ROC analysis demonstrated modest but statistically significant discrimination (AUC = 0.626, 95% CI: 0.55–0.70, p = 0.009).
Conclusions
Serum FGF23 levels are independently associated with CAC in PD patients and may contribute to cardiovascular risk stratification. Although its predictive performance alone is modest, FGF23 may enhance current cardiovascular risk assessment models in this high‐risk population. Trial Registration: Medical Research Registration: MR‐33‐22‐013114
Förderung
- Science and Technology Program of Zhejiang Province
Zitieren
APA
Xie, H., Si, Y., Wang, H., Wang, X., Bao, G., Gong, S., Shen, S., Wang, Y., Shan, J., Gong, T., Yang, Y., & Guan, J. (2026). Association Between Serum FGF23 Levels and Coronary Artery Calcification in Peritoneal Dialysis Patients. International Journal of Clinical Practice, 2026(1). https://doi.org/10.1155/ijcp/5868344
Vancouver
Xie H, Si Y, Wang H, Wang X, Bao G, Gong S, et al. Association Between Serum FGF23 Levels and Coronary Artery Calcification in Peritoneal Dialysis Patients. International Journal of Clinical Practice. 2026;2026(1). doi:10.1155/ijcp/5868344
BibTeX
@article{Xie2026,
author = {Xie, Haiying and Si, Yuhe and Wang, Hongyao and Wang, Xiaoling and Bao, Guoxiang and Gong, Shuwen and Shen, Shuijuan and Wang, Yanyan and Shan, Juanping and Gong, Tujian and Yang, Yanru and Guan, Jichao},
title = {Association Between Serum FGF23 Levels and Coronary Artery Calcification in Peritoneal Dialysis Patients},
journal = {International Journal of Clinical Practice},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/ijcp/5868344}
}
EUVIMED